StockData
Natures Sunshine Products Inc logo

Natures Sunshine Products Inc (NATR) stock

NATRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3058% below fair value
$10.33−0.23 (-2.18%)

Close on Nov 17, 2026Market cap $181.76MP/E 10.2Yield –

Natures Sunshine Products r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $1.90M, up 11.8% from the year before. Over ten years it grew -3.8% a year on average. The highest annual figure on record is $3.40M in fiscal 2017.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.90M+11.8%
FY2024Dec 31, 2024$1.70M+6.3%
FY2023Dec 31, 2023$1.60M+6.7%
FY2022Dec 31, 2022$1.50M+7.1%
FY2021Dec 31, 2021$1.40M-6.7%
FY2020Dec 31, 2020$1.50M-28.6%
FY2019Dec 31, 2019$2.10M-25.0%
FY2018Dec 31, 2018$2.80M-17.6%
FY2017Dec 31, 2017$3.40M+6.3%
FY2016Dec 31, 2016$3.20M+14.3%
FY2015Dec 31, 2015$2.80M+12.0%
FY2014Dec 31, 2014$2.50M+25.0%
FY2013Dec 31, 2013$2.00M+36.6%
FY2012Dec 31, 2012$1.46M-5.7%
FY2011Dec 31, 2011$1.55M-23.2%
FY2010Dec 31, 2010$2.02M–

More Natures Sunshine Products figures

See a number that looks wrong?